TRN-261 is under clinical development by Tris Pharma and currently in Phase II for Pain. According to GlobalData, Phase II drugs for Pain have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TRN-261’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TRN-261 is under development for the treatment of acute and chronic pain.
Tris Pharma overview
Tris Pharma discovers, develops and commercializes over-the-counter and generic products. The company’s pipeline product candidates include TRN-110, TRN-124, TRN-125, TRN-167, TRN-123, TRN-152, TRN-148, TRN-219, TRN-213 and TRN-226. Its generic products include colesevelam, dexmethylphenidate, dextroamphetamine, doxycycline Hyclate, doxycycline hyclate, droxidopa, febuxostat, hydrocodone, hydrocodone polistirex, lacosamide, methylphenidate, morphine sulfate and paliperidone ER. Tris Pharma is headquartered in South Brunswick, New Jersey, the US.
For a complete picture of TRN-261’s drug-specific PTSR and LoA scores, buy the report here.